# Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)

> **NCT02138825** · PHASE2 · TERMINATED · sponsor: **Bayer** · enrollment: 147 (actual)

## Conditions studied

- Idiopathic Interstitial Pneumonias / Hypertension,Pulmonary

## Interventions

- **DRUG:** Riociguat (Adempas, BAY63-2521)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02138825
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-06-04
- **Primary completion:** 2016-05-05
- **Final completion:** 2016-09-14
- **Target enrollment:** 147 (ACTUAL)
- **Why stopped:** Study terminated per recommendation of iDMC. On iDMC request, protocol amended to include 4-month safety follow-up for patients after withdrawal of riociguat.
- **Last updated:** 2017-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02138825

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02138825, "Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT02138825. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*